SU2C Expands Scientific Advisory Committee with New Cancer Research Leaders
Stand Up To Cancer (SU2C) has expanded its Scientific Advisory Committee with the appointment of several new members. The 30-member committee, led by a chair and supported by two vice-chairs, plays a central role in shaping the organization's research funding priorities and providing guidance on key scientific initiatives.
Throughout its 18-year history, SU2C's Scientific Advisory Committee has brought together many of the nation's foremost cancer researchers from a wide range of specialties and institutions, ensuring diverse scientific expertise and informed decision-making.
"The field of cancer research continues to advance at an extraordinary pace, creating both exciting opportunities and new challenges in our mission to accelerate meaningful progress against cancer," said SU2C President and CEO Julian Adams, PhD. "The Scientific Advisory Committee is essential to our ability to build on our legacy of funding transformative research that delivers real benefits for patients and their families."
The newly appointed committee members are:
Throughout its 18-year history, SU2C's Scientific Advisory Committee has brought together many of the nation's foremost cancer researchers from a wide range of specialties and institutions, ensuring diverse scientific expertise and informed decision-making.
"The field of cancer research continues to advance at an extraordinary pace, creating both exciting opportunities and new challenges in our mission to accelerate meaningful progress against cancer," said SU2C President and CEO Julian Adams, PhD. "The Scientific Advisory Committee is essential to our ability to build on our legacy of funding transformative research that delivers real benefits for patients and their families."
The newly appointed committee members are:
- Adrian Bot, MD, PhD – Venture Partner at RA Ventures and former Chief Scientific Officer at Capstan Therapeutics
- Lisa Butterfield, PhD – Cancer immunotherapy consultant and former Distinguished Scientist at Merck
- Christina Curtis, PhD – Senior Vice Chair of Research, Department of Medicine, and Director of Artificial Intelligence and Cancer Genomics at Stanford Cancer Institute
- Shawna Hudson, PhD – Professor, Vice Chair of Research, and Henry Rutgers Chair of Family Medicine and Community Health at Rutgers Robert Wood Johnson Medical School; Co-chair of the SU2C Health Disparities Committee
- Trey Ideker, PhD – Professor in the Department of Medicine at UC San Diego and Director of the Big Data Institute at Oxford University
- Martin Pomper, MD, PhD – Professor and Chair of Radiology at the University of Texas Southwestern Medical Center
- Trevor Pugh, PhD – Senior Scientist at UHN's Princess Margaret Cancer Centre, Director of Genomics at the Ontario Institute for Cancer Research, and Professor at the University of Toronto
- Srikant Ramaswami, JD, MS – Founder and Principal of Sri Spoke Communications LLC and former Senior Vice President and Global Head of Corporate Affairs and Investor Relations at Galapagos NV
The Scientific Advisory Committee is chaired by William G. Nelson, MD, PhD, Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine. Serving as vice-chairs are John Carpten, PhD, Director of the City of Hope Cancer Center, and Arnold Levine, PhD, Emeritus Professor at the Institute for Advanced Study.
Companies